What is OrbusNeich?
Founded in 2000 and headquartered in Hong Kong, OrbusNeich operates as a global pioneer in the provision of advanced vascular solutions. The company specializes in the design, development, and manufacturing of high-performance medical devices that address complex cardiovascular conditions. By maintaining a rigorous focus on clinical outcomes and technological innovation, OrbusNeich has established itself as a critical partner for healthcare providers worldwide. Its extensive product portfolio is engineered to meet the evolving demands of interventional cardiology, reflecting a deep commitment to improving patient quality of life through precision engineering and evidence-based medical practices.
How much funding has OrbusNeich raised?
OrbusNeich has raised a total of $200M across 1 funding round:
Unspecified
$200M
Unspecified (2021): $200M with participation from CCB International, Shenzhen Capital Group, and China International Capital
Key Investors in OrbusNeich
CCB International
A comprehensive investment services firm owned by China Construction Bank, specializing in pre-IPO, IPO, and post-IPO capital market services.
Shenzhen Capital Group
A prominent venture capital firm focused on supporting high-growth technology and innovation-driven enterprises across various industrial sectors.
China International Capital
A full-service investment banking institution providing research-based financial solutions, wealth management, and strategic investment advisory services.
What's next for OrbusNeich?
Looking ahead, the strategic deployment of the $200M capital will likely focus on deepening the company's penetration into emerging markets and enhancing its pipeline of next-generation vascular intervention tools. As the firm transitions into a more mature phase of its lifecycle, the emphasis will shift toward optimizing supply chain efficiencies and fostering collaborative partnerships with global research institutions. This strategic roadmap is designed to sustain the company's competitive advantage, ensuring that OrbusNeich remains a dominant force in the vascular intervention landscape while navigating the complexities of the global healthcare regulatory environment.
See full OrbusNeich company page